
Product Data Sheet

Product Name: AVX 13616
 Cat. No.: GC35439

Chemical Properties

Cas. No. 900814-48-4
 SMILES O=C(NC(CCCCN)C(NC(CCCNC(N)=N)C(NC(CC(C)C)C(OCCC(C)C)=O)=O)=O)COC1=C(C(C(C=CC=C2)=C2C=C3)=C3OCCC(C)C)C(C=C
 Formula C₅₀H₇₃Cl₂N₇O₇ M.Wt 955.06
 Solubility Soluble in DMSO Storage Store at -20°C
 General For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be tips for several months.
 Shipping Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.
 Condition
 Structure

Background

AVX 13616 shows the potent in vivo antibacterial activity of Avexa's lead antibacterial candidate; particularly against drug-resistant Staphylococcus pathogens. IC50 value: 2-4 ug/ml (MICs) Target: antibacterial agent AVX13616 was as active as mupirocin in a nasal decolonization model but required only a single application. The compounds are being developed for topical indications and/or wound infection/catheter-related infections. AVX13616 and other compounds showed broad spectrum antibacterial activity against a range of isolates with MICs of 2-4 micrograms per millilitre against S. aureus, coagulase negative staphylococci, enterococci, MRSA, VISA and VRSA. A single application of 5% (w/w) AVX13616 (approximately equimolar to 2% mupirocin) was as effective as 2% mupirocin administered twice a day for five days in nasal decolonisation of MRSA in mice.

[1]. Avexa Presents Data from Apricitabine and Antibacterial Programs at two International Conferences

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA
